Latest news with #AdcockIngramHoldings
Time of India
6 days ago
- Business
- Time of India
Natco Pharma offers to acquire nearly 36% stake in Adcock Ingram in Rs 2,100-cr deal
Natco Pharma on Wednesday said it has offered to acquire nearly 36 per cent stake in South African drug firm Adcock Ingram Holdings for up to Rs 2,100 crore in a cash deal. The Hyderabad-based firm said it has submitted a firm intention offer to Adcock Ingram Holdings to buy out minority shareholders for a cash offer of R75 (USD 4.271) per share. Explore courses from Top Institutes in Please select course: Select a Course Category Artificial Intelligence Leadership Public Policy others Healthcare Degree Data Science Data Analytics Others MCA healthcare Design Thinking CXO Technology Operations Management PGDM MBA Management Finance Product Management Project Management Data Science Digital Marketing Cybersecurity Skills you'll gain: Duration: 7 Months S P Jain Institute of Management and Research CERT-SPJIMR Exec Cert Prog in AI for Biz India Starts on undefined Get Details Should the offer be accepted, the company will hold a 35.75 per cent stake in Adcock Ingram, valued at R4 billion (USD 226 million), it stated in a regulatory filing. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Struggling With Belly Fat? Try This at Home Home Fitness Hack Shop Now Undo The acquisition amounts to 51,643,319 equity shares resulting in Natco shareholding to arrive at 35.75 per cent of the paid-up equity share capital in aggregate, it said. Adcock Ingram is estimated at a valuation of R11 billion (USD 632 million). Live Events It is envisaged that post-acquisition, Adcock will continue to operate as a private South African business, supported by two substantial strategic shareholders, Bidvest at 64.25 per cent and Natco at 35.75 per cent, including a prior held stake, the company stated. Natco currently holds 0.80 per cent in Adcock Ingram. "The proposed transaction will provide NATCO Pharma with a well-established entry into the Southern African market. It will also allow NATCO Pharma to tap into new revenue streams and expand our footprint in one of the largest and growing emerging markets , while providing a gateway to the African continent," Natco Pharma CEO & Vice Chairman Rajeev Nannapaneni said. Adcock Ingram generated a revenue of R9.6 billion (USD 536 million) in the last financial year and delivered a gross margin of 33.4 per cent. "This is a significant moment in our company's long history. This offer represents a huge vote of confidence in Adcock Ingram's people, brands and business model, and the South African healthcare environment," Andrew Hall, CEO, Adcock Ingram Holdings, stated. Adcock Ingram will benefit from a partnership with a research-focused, innovative and vertically integrated pharmaceutical company, and over time South Africans will be beneficiaries of wider access to affordable medicines , he added. In addition, the offer represents an attractive premium for the minority shareholders, who have supported company over the years, he said. The estimated transaction completion time is four months, assuming no regulatory delays, Natco Pharma said. Business operations will remain uninterrupted, with no changes to existing partnerships, joint ventures, or supplier relationships, it noted. Natco Pharma shares ended 1.99 per cent up at Rs 1,034.50 apiece on BSE.
News18
6 days ago
- Business
- News18
Natco offers to acquire nearly 36 pc stake in Adcock Ingram in Rs 2,100-cr deal
New Delhi, Jul 23 (PTI) Natco Pharma on Wednesday said it has offered to acquire nearly 36 per cent stake in South African drug firm Adcock Ingram Holdings for up to Rs 2,100 crore in a cash deal. The Hyderabad-based firm said it has submitted a firm intention offer to Adcock Ingram Holdings to buy out minority shareholders for a cash offer of R75 (USD 4.271) per share. Should the offer be accepted, the company will hold a 35.75 per cent stake in Adcock Ingram, valued at R4 billion (USD 226 million), it stated in a regulatory filing. The acquisition amounts to 51,643,319 equity shares resulting in Natco shareholding to arrive at 35.75 per cent of the paid-up equity share capital in aggregate, it said. Adcock Ingram is estimated at a valuation of R11 billion (USD 632 million). It is envisaged that post-acquisition, Adcock will continue to operate as a private South African business, supported by two substantial strategic shareholders, Bidvest at 64.25 per cent and Natco at 35.75 per cent, including a prior held stake, the company stated. Natco currently holds 0.80 per cent in Adcock Ingram. 'The proposed transaction will provide NATCO Pharma with a well-established entry into the Southern African market. It will also allow NATCO Pharma to tap into new revenue streams and expand our footprint in one of the largest and growing emerging markets, while providing a gateway to the African continent," Natco Pharma CEO & Vice Chairman Rajeev Nannapaneni said. Adcock Ingram generated a revenue of R9.6 billion (USD 536 million) in the last financial year and delivered a gross margin of 33.4 per cent. 'This is a significant moment in our company's long history. This offer represents a huge vote of confidence in Adcock Ingram's people, brands and business model, and the South African healthcare environment," Andrew Hall, CEO, Adcock Ingram Holdings, stated. Adcock Ingram will benefit from a partnership with a research-focused, innovative and vertically integrated pharmaceutical company, and over time South Africans will be beneficiaries of wider access to affordable medicines, he added. In addition, the offer represents an attractive premium for the minority shareholders, who have supported company over the years, he said. The estimated transaction completion time is four months, assuming no regulatory delays, Natco Pharma said. Business operations will remain uninterrupted, with no changes to existing partnerships, joint ventures, or supplier relationships, it noted. Natco Pharma shares ended 1.99 per cent up at Rs 1,034.50 apiece on BSE. PTI MSS HVA view comments First Published: July 23, 2025, 17:30 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Yahoo
21-05-2025
- Business
- Yahoo
Adcock Ingram Holdings Limited (JSE:AIP) stock most popular amongst private equity firms who own 65%, while individual investors hold 18%
The considerable ownership by private equity firms in Adcock Ingram Holdings indicates that they collectively have a greater say in management and business strategy 65% of the company is held by a single shareholder (BB Investment Co. (Pty) Ltd.) 15% of Adcock Ingram Holdings is held by Institutions Our free stock report includes 1 warning sign investors should be aware of before investing in Adcock Ingram Holdings. Read for free now. If you want to know who really controls Adcock Ingram Holdings Limited (JSE:AIP), then you'll have to look at the makeup of its share registry. We can see that private equity firms own the lion's share in the company with 65% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Individual investors, on the other hand, account for 18% of the company's stockholders. Let's take a closer look to see what the different types of shareholders can tell us about Adcock Ingram Holdings. View our latest analysis for Adcock Ingram Holdings Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. As you can see, institutional investors have a fair amount of stake in Adcock Ingram Holdings. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Adcock Ingram Holdings, (below). Of course, keep in mind that there are other factors to consider, too. Hedge funds don't have many shares in Adcock Ingram Holdings. Our data shows that BB Investment Co. (Pty) Ltd. is the largest shareholder with 65% of shares outstanding. This implies that they have majority interest control of the future of the company. Meanwhile, the second and third largest shareholders, hold 9.7% and 1.7%, of the shares outstanding, respectively. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. We note our data does not show any board members holding shares, personally. It is unusual not to have at least some personal holdings by board members, so our data might be flawed. A good next step would be to check how much the CEO is paid. The general public, who are usually individual investors, hold a 18% stake in Adcock Ingram Holdings. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. Private equity firms hold a 65% stake in Adcock Ingram Holdings. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public. I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For example, we've discovered 1 warning sign for Adcock Ingram Holdings that you should be aware of before investing here. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-02-2025
- Business
- Yahoo
Adcock Ingram Holdings First Half 2025 Earnings: EPS: R2.66 (vs R2.91 in 1H 2024)
Revenue: R4.71b (flat on 1H 2024). Net income: R389.7m (down 12% from 1H 2024). Profit margin: 8.3% (down from 9.4% in 1H 2024). EPS: R2.66 (down from R2.91 in 1H 2024). All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Pharmaceuticals industry in Africa. Performance of the market in South Africa. The company's shares are down 10.0% from a week ago. We don't want to rain on the parade too much, but we did also find 1 warning sign for Adcock Ingram Holdings that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
